Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perampanel in Post-Herpetic Neuralgia (PHN)
NCT00592774Phase 2Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Jan 2008
- Primary completion
- Dec 2008
- Modality
- Classical Binding Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of perampanel in postherpetic neuralgia (PHN) (5 cohorts), sponsored by Eisai Co., Ltd. Primary endpoints: Change From Baseline in Average Pain Scores to Week 15/ End of Treatment (EOT), Responder Rate: Subjects With at Least 30 Percent Reduction in Pain at 15 weeks and 2 more. Started Jan 2008; status: completed.
02
Drugs
perampanel
03
Conditions
postherpetic neuralgia (PHN)
Beyond the preview
Go deeper on NCT00592774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00592774.